Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 11 more

Conditions: Glaucoma
Interventions: XEN Group, Phacoemulsification; Device · Procedure
Lead sponsor: Allergan; Industry
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hypertensive Disorder of Pregnancy, Preeclampsia
Interventions: Treating BP acutely with intravenous or rapid acting oral medications; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more

Conditions: Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Nutrition, Healthy, Type 2 Diabetes, Hypertension, Dyslipidemias
Interventions: Food resource coaching, Free community food support, Medically tailored groceries; Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Health Behavior
Interventions: Tracking plus coaching; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%, Timolol 0.05% eye drops; Drug
Lead sponsor: Tavo Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Lynchburg, Virginia

Conditions: Gout, Hyperuricemia
Interventions: Subsidy for food purchases and dietitian education; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Woodlawn, Maryland • Boston, Massachusetts

Conditions: Hypertension, Hypercortisolemia, Cushing Syndrome
Interventions: Osilodrostat, Placebo; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Jacksonville, Florida • Canton, Ohio • Weslaco, Texas

Conditions: Hypertension
Interventions: LED bed; Device
Lead sponsor: LED Intellectual Properties, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rockdale, Texas

Conditions: Hypertension, Vascular Stiffness, Aging
Interventions: Blood pressure treatment algorithm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin

Conditions: Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospitalization, Traditional inpatient hospitalization; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: SK&F-105517 (COREG CR FDC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Hackensack, New Jersey • Austin, Texas

Conditions: Hypertension
Interventions: Direct input of home blood pressure readings via MyChart; Other
Lead sponsor: Loyola University; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions: Right Heart Catheterization, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Radiotracer, Hypertension, Cholesterol
Interventions: Dexamethasone (Group 2), Cosyntropin (Group 3), PET/CT Scan with FNP-59; Drug · Combination Product
Lead sponsor: Benjamin Viglianti; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Grand Rapids, Michigan

Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions: PC2: Primary Care Connect; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Glaucoma
Interventions: Baerveldt Glaucoma Implant 350-mm2 / BG101-350, Transscleral Diode Laser Cyclophotocoagulation, Ahmed Model FP7 Flexible Plate, Baerveldt Glaucoma Implant 250-mm2 / BG103-250; Device · Procedure
Lead sponsor: Robert Feldman; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 18 more

Conditions: Cardiovascular Diseases, Blood Pressure, Hypertension
Interventions: VicorderCS; Device
Lead sponsor: 80 Beats Medical; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Breckenridge, Colorado

Conditions: Hypertension, Sleep Apnea Syndromes, Obesity
Interventions: 1000 extra calories; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Nanodropper, Regular dropper; Device
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Hypertension, Pulmonary
Interventions: Carbon Monoxide; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

Blood Pressure Goal in Preterm Preeclampsia

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Evaluation of Patients With Known or Suspected Heart Disease

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Medically Tailored Groceries and Food Resource Coaching

Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure

A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.

The Diet Gout Trial

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A Controlled Study to Investigate the Effect of Multi-wave Light Emitting Diode (LED) Bed on Blood Pressure and Endothelial Function

Arterial Stiffness and Blood Pressure

Hospital-Level Care at Home for Acutely Ill Adults

A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure

The Feasibility of a Web-based Application to Monitor Home Blood Pressure

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)

VicorderCS NIBP Validation Study to Review The Ability to Capture Blood Pressure Measurements

Fat Gain and Cardiovascular Disease Mechanisms

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension